Cargando…
Why, Who, When, and How? Rationale for Considering Allogeneic Stem Cell Transplantation in Children with Sickle Cell Disease
Considering the progress made in the management of sickle cell disease during the past 30 years, along with the excellent results obtained with hematopoietic stem cell transplantation (SCT), it is important to reexamine why, who, when and how to recommend allogeneic SCT in children with sickle cell...
Autor principal: | Bernaudin, Françoise |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833062/ https://www.ncbi.nlm.nih.gov/pubmed/31546720 http://dx.doi.org/10.3390/jcm8101523 |
Ejemplares similares
-
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
por: Loke, Justin, et al.
Publicado: (2021) -
Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease
por: Saraf, Santosh L., et al.
Publicado: (2019) -
Allogeneic Hematopoietic Cell Transplantation in the Treatment of Chronic Lymphocytic Leukemia: Why and When?
por: Delioukina, Maria L., et al.
Publicado: (2010) -
Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: A review
por: Bhalla, Nishka, et al.
Publicado: (2023) -
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
por: Jiang, Huiwen, et al.
Publicado: (2020)